Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

<p>Abstract</p> <p>Because of its low toxicity, low-dose (LD) chemotherapy is ideally suited for combination with antiangiogenic drugs. We investigated the impact of tumor vascular endothelial growth factor A (VEGF-A) expression on the efficacy of LD paclitaxel chemotherapy and its...

Full description

Bibliographic Details
Main Authors: Leiby Benjamin, Alagkiozidis Ioannis, Zhang Lin, Mohamed-Hadley Alisha, Krafty Robert T, Holtz David O, Guo Wensheng, Gimotty Phyllis A, Coukos George
Format: Article
Language:English
Published: BMC 2008-01-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/6/1/2

Internet

http://www.translational-medicine.com/content/6/1/2

Similar Items